Prenatal drug exposure and teratological risk: One-year experience of an Italian Teratology Information Service

Medical Science Monitor

Volumn 14, Issue 2, 2008, Pages

  De Santis, Marco ^a,b   Cesari, Elena ^a   Ligato, Maria Serena ^a   Nobili, Elena ^a   Straface, Gianluca ^a   Cavaliere, Annafranca ^a   Caruso, Alessandro ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Drugs surveillance; Maternal anxiety; Prenatal drug exposure; Teratological risk; Teratology information service

Indexed keywords

ANTICONVULSIVE AGENT; ANTITHYROID AGENT; COUMARIN DERIVATIVE; ERGOTAMINE; LITHIUM; MISOPROSTOL; RETINOID; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; FEMALE; FETUS; FETUS OUTCOME; FETUS RISK; HUMAN; ITALY; PATIENT COUNSELING; PERCEPTION; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PRENATAL DRUG EXPOSURE; TERATOGENICITY; UNPLANNED PREGNANCY;

ANTICONVULSANTS; ANTITHYROID AGENTS; COUNSELING; FEMALE; HUMANS; INFANT, NEWBORN; INFORMATION SERVICES; ITALY; LITHIUM; MATERNAL EXPOSURE; PREGNANCY; PUBLIC HEALTH; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; TERATOGENS; TERATOLOGY;

EID: 39349109450     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (155)

1. nd ed. New York: Marcel Dekker, 1994
2. Clementi M, Di Gianantonio E, Ornoy A: Teratology information services in Europe and their contribution to the prevention of congenital anomalies. Community Genet, 2002; 5: 8-12
3. Eléfant E, Boyer M, Boyer P et al: Teratogenic agent information centre: fifteen years of counseling and pregnancy follow-up. Teratology, 1992; 46: 35-44
4. Garbis JM, Robert E, Peters PWJ: Experience of two teratology information services in Europe. Teratology, 1990; 42: 629-34
5. De Santis M, Straface G, Cavaliere AF et al: Teratological risk evaluation and prevention of voluntary abortion. Minerva Ginecol, 2006; 58(2): 91-99
6. Hancock RL, Koren G, Einarson A, Ungar WJ: The effectiveness of Teratology Information Service (TIS) Reprod Toxicol, 2006; 2382: 125-32 Epub Nov 18
7. Available at: www.entis-org.com. Accessed on August 7, 2007
8. Schumacher GH: Teratology in cultural documents and today. Ann Anat, 2004;186(5-6): 539-46
9. De Santis M, Straface G, Carducci B et al: Risk of drug induced congenital defects Eur J Obst Gyn Repr Biol, 2004; 117(1): 10-19
10. Pole M, Einarson A, Pairaudeau N et al: Drugs labelling and risk perception of teratogenicity: a survey of pregnancy Canadian women and their health professionals. J Clin Pharm, 2000; 40: 573-77
11. Goldstein DJ, Corbin LA, Sundell KL: Effects of fi rst-trimester fluoxetine exposure on the newborn. Obstet Gynecol, 1997; 89(5): 713-18
12. Kulin NA, Pastuszak A, Sage SR et al: Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA, 1998; 279(8): 609-10
13. Ericson A, Kallen B, Wiholm B: Delivery outcome after the use of antidepressants in early pregnancy Eur J Clin Pharmacol, 1999; 55(7): 503-8
14. Hendrick V, Smith LM, Suri R et al: Birth outcomes after prenatal exposure to antidepressant medication Am J Obst Gynec, 2003; 188(3): 812-15
15. Malm H, Klaukka T, Neuvonen PJ: Risks associated with selective serotonin reuptake inhibitors in pregnancy Obstet Gynecol, 2005; 106(6): 1289-96
16. Wen SW, Yang Q, Garner P et al: Selective serotonin reuptake inhibitors and adverse pregnancy outcomes Am J Obst Gyn, 2006; 194(4): 961-66
17. Einarson TR, Einarson A: Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf, 2005; 14(12): 823-27
18. Available on: http://www.fda.gov/cder/drug/advisory/paroxetine200512. htm
19. GSK Advisory October 2005. Available at: http://ctr.gsk.co.uk/Summary/ paroxetine/studylist.asp
20. GSK Advisory Dec 2005 Available at: http://ctr.gsk.co.uk/Summary/ paroxetine/studylist.asp
21. Diav Citrin O, Shechtman S, Weinbaum D et al: Paroxetine and Fluoxetine in pregnancy: controlled study (abstract) Reprod Toxicol, 2005; 20: 459
22. Cole A: Paroxetine in the fi rst trimester and prevalence of congenital malformations. (abstract). International Society of Pharmacoepidemiology Meeting; 2006, Lisbon, Portugal
23. Kallen B, Otterblad Olausson P: Antidepressant drugs during pregnancy and infant congenital heart defects. Reprod Toxicol, 2006; 21(3): 221-22
24. Chambers CD, Hernandez-Diaz S, Van Marter LJ et al: Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med, 2006; 354(6): 579-87
25. ACOG committee on obstetric practice. Committee opinion no 354: treatment with selective serotonin reuptake inhibitors during pregnancy. Obst Gyn, 2006; 108(6): 1601-3
26. Pennell PB: The importance of monotherapy in pregnancy. Neurology, 2003; 60(11): S31-38
27. Arpino C, Brescianini S, Robert E et al: Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE). Epilepsia, 2000; 41: 1436-43
28. Dessens AB, Cohen-Kettenis PT, Mellenbergh GJ et al: Association of prenatal phenobarbital and phenytoin exposure with genital anomalies and menstrual disorders. Teratology, 2001; 64: 181-88
29. Holmes LB, Wyszynski DF, Lieberman E: The AED (Antiepileptic Drug) Pregnancy Registry. A 6-year experience. Arch Neurol, 2004; 61: 673-78
30. Thorp JA, O'Connor M, Jones AM et al: Does perinatal phenobarbital exposure affect developmental outcome at age 2? Am J Perinatol, 1999; 16: 51-60
31. Adams J, Harvey EA, Holmes LB: Cognitive defi cits following gestational monotherapy with phenobarbital and carbamazepine. Neurotoxicol Teratol, 2000; 22: 466
32. Canger R, Battino D, Canevini MP et al: Malformations in offspring of women with epilepsy: a prospective study. Epilepsia, 1999; 40(9): 1231-36
33. Azarbayjani F, Borg LA, Danielsson BR: Increased susceptibility to phenytoin teratogenicity: excessive generation of reactive oxygen species or impaired antioxidant defence? Basic Clin Pharmacol Toxicol, 2006; 99(4): 305-11
34. Omtzigt JG, Los FJ, Hagenaars AM et al: Prenatal diagnosis of spina bifi da aperta after first-trimester valproate exposure. Prenat Diagn, 1992; 12(11): 893-97
35. Tatum WO: Use of antiepileptic drugs in pregnancy. Expert Rev Neurother, 2006; 6(7): 1077-86
36. Holmes L, Wyszynski D, Mittendorf R: Evidence for an increased risk of birth defects in the offspring of women exposed to valproate during pregnancy: fi ndings from the AED pregnancy registry. Am J Obstet Gynecol, 2002; 187: S137
37. Vinten J, Adab N, Kini U et al: Liverpool and Manchester Neurodevelopment Study Group. Neuropsychological effects of exposure to anticonvulsivant medication in utero. Neurology, 2005; 64(6): 949-54
38. Motamedi GK, Meador KJ: Antiepileptic drugs and neurodevelopment. Curr Neurol Neurosci Rep, 2006; 6(4): 341-46
39. Hanson JW, Buehler BA: The fetal hydantoin syndrome. J Pediatr, 1982; 101: 816-18
40. Hansen DK, Billings RE: Phenytoin teratogenicity and effects on embryonic and maternal folate metabolism. Teratology, 1985; 31: 71
41. Buehler BA, Conover B: Prenatal diagnosis of the fetal hydantoin syndrome: practical considerations. Reprod Toxicol, 1993; 7: 161-62
42. Buehler BA, Bick D, Delimont D: Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med, 1993; 329: 1660-61
43. Sherman S, Roizen N: Fetal hydantoin syndrome and neuroblastoma. Lancet, 1976; 2: 517
44. Matalon S, Schechtman S, Goldzweig G, Ornoy A: The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol, 2002; 16(1): 9-17
45. Pearse SB, Rodriguez LAG, Hartwell C, Russell G: A pregnancy register of patients receiving carbamazepine in the UK. Pharmacoepidemiol Drug Saf, 1992; 1: 321-25
46. Scolnik D, Nulman I, Rovet J et al: Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA, 1994; 271: 767-70
47. Jones KL, Lacro RV, Johnson KA, Adams J: Pregnancy outcome in women treated with tegretol. Teratology, 1988; 37: 468
48. Ornoy A, Cohen I: Follow-up studies of children born to epileptic women treated with carbamazepine. Teratology, 1995; 51: 169
49. Hesdorffer DC: Spina bifi da in infants of women taking carbamazepine. Lancet, 1991; 325: 664
50. Oakeshott P, Hunt GM: Carbamazepine and spina bifi da. Br Med J, 1991; 303: 651
51. Johannessen SI, Tomson T: Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet, 2006; 45(11): 1061-75
52. Wilby J, Kainth A, Hawkins N et al: Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess, 2005; 9(15): 1-157
53. Eisenschenk S: Treatment with oxcarbazepine during pregnancy. Neurologist, 2006; 12(5): 249-54
54. Kretz R, Coban I, Gaus V, Schmitz B: EURAP: the European Registry of Antiepileptic Drugs and Pregnancy Nervenarzt, 2006; 77(6): 722,724-28
55. Montouris G: Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr Med Res Opin, 2005; 21(5): 693-701
56. Prakash, Prabhu LV, Nasar MA et al: Lamotrigine in pregnancy: safety profi le and the risk of malformations. Singapore Med J, 2007; 48(10): 880-83
57. Tettenborn B: Management of epilepsy in women of childbearing age: practical recommendations. CNS Drugs, 2006; 20(5): 373-87
58. Pack AM: Therapy Insight: clinical management of pregnant women with epilepsy. Nat Clin Pract Neurol, 2006; 2(4): 190-200
59. Koren G, Nava-Ocampo AA, Moretti ME et al: Major malformations with valproic acid. Can Fam Physician, 2006; 52: 441-42,444,447
60. Kalviainen R, Tomson T: Optimizing treatment of epilepsy during pregnancy. Neurology, 2006; 67: S59-63
61. Casey BM, Leveno KJ: Thyroid disease in pregnancy. Obstet Gynecol, 2006; 108(5): 1283-92
62. Chattaway JM, Klepser TB: Propylthiouracil versus methimazole in treatment of Graves' disease during pregnancy. Ann Pharmacother, 2007; 41(6): 1018-22
63. Milham Jr: Scalp defects in infants of mothers treated for hyperthyroidism with methimazole or carbimazole during pregnancy. Teratology, 1985; 32: 321
64. Bachrach LK, Burrow GN: Aplasia cutis congenital and methimazole. Can Med Assoc J, 1984; 130: 1264
65. Martinez-Frias ML, Cereijo A, Rodriguez-Pinilla E, Urioste M: Methimazole in animal feed and congenital aplasia cutis. Lancet 1992; 339: 742-43
66. Vogt T, Stolz W, Landthaler M: Aplasia cutis congenital after exposure to methimazole: a causal relationship? Br J Dermatol, 1995; 133: 994-96
67. Clementi M, Di Gianantonio E, Pelo E et al: Methimazole embryopathy: delineation of the phenotype. Am J Med Genet, 1999; 83: 43-46
68. Di Gianantonio E, Schaefer C, Mastroiacovo PP et al: Adverse effects of prenatal methimazole exposure. Teratology, 2001; 64: 262-66
69. Atkins P, Cohen SB, Phillips BJ: Drug therapy for hyperthyroidism in pregnancy: safety issues for mother and fetus. Drug Saf, 2000; 23(3): 229-44
70. Clark SM, Saade GR, Snodgrass WR, Hankins GD: Pharmacokinetics and pharmacotherapy of thionamides in pregnancy. Ther Drug Monit, 2006; 28(4): 477-83
71. Azizi F: The safety and effi cacy of antithyroid drugs. Expert Opin Drug Saf, 2006; 5(1): 107-16
72. Thyroid disease in pregnancy. ACOG Technical Bulletin Number 181-June 1993. Int J Gynaecol Obstet, 1993; 43: 82-88
73. Burrow GN, Bartsocas C, Klatskin EH, Grunt JA: Children exposed in utero to propylthiouracil. Subsequent intellectual and physical development. Am J Dis Child, 1968; 116: 161-66
74. Momotani N, Noh JY, Ishikawa N, Ito K: Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. J Clin Endocrinol Metab, 1997; 82: 3633-36
75. Kibirige MS, Hutchison S, Owen CJ, Delves HT: Prevalence of maternal dietary iodine insufficiency in the north east of England: implications for the fetus. Arch Dis Child Fetal Neonatal Ed, 2004; 89(5): F436-39
76. Coakley JC, Francis I, Gold H et al: Transient primary hypothyroidism in the newborn: experience of the Victorian Neonatal Thyroid Screening Programme. Aust Paediatr J, 1989; 25(1): 25-30
77. Wolff J: Iodide goitre and the pharmacologic effects of excess iodide. Am J Med, 1969; 47: 101-24
78. Delange F: Iodine defi ciency in Europe and its consequences: an update. Eur J Nucl Med Mol Imaging, 2002; 29: S404-16
79. Committee on Drugs, American Academy of Pediatrics: Adverse reactions to iodide therapy of asthma and other pulmonary diseases. Pediatrics, 1982; 57: 272-74
80. Newport DJ, Viguera AC, Beach AJ et al: Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry, 2005; 162(11): 2162-70
81. Giles JJ, Bannigan JG: Teratogenic and developmental effects of lithium. Curr Pharm Des, 2006; 12(12): 1531-41
82. Ortigado Matamala A, Garcia Garcia A, Jimenez Bustos JM: Ebstein's anomaly and lithium exposure during pregnancy. An Pediatr (Barc), 2006; 65(6): 626-27
83. Grover S, Avasthi A, Sharma Y: Psychotropic in pregnancy: weighing the risks. Indian J Med Res, 2006; 123(4): 497-512
84. Giles JJ, Bannigan JG: Teratogenic and developmental effects of lithium. Curr Pharm Des, 2006; 12(12): 1531-41
85. Ishikawa SE: Transient diabetes insipidus. Nippon Rinsho, 2006; 28(S1): 190-92
86. Ward S, Wisner KL: Collaborative management of women with bipolar disorder during pregnancy and postpartum: pharmacologic considerations. J Midwifery Women Health, 2007; 52(1): 3-13
87. Einarson A: The safety of psychotropic drug use during pregnancy: a review. Med Gen Med, 2005; 7(4): 3
88. Perlis RH, Sachs GS, Lafer B: Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data. Am J Psychiatry, 2002; 159(7): 1155-59
89. Schou M: Lithium treatment during pregnancy, delivery, and lactation: an update. J Clin Psychiatry, 1990; 51(10): 410-13
90. Sathienkijkanchai A, Wasant P: Fetal warfarin syndrome. J Med Assoc Thai, 2005; 88: S246-50
91. Hall JAG, Paul RM, Wilson KM: Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med, 1980; 68: 122-40
92. Schaefer C, Hannemann D, Meister R et al: Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost, 2006; 95(6): 949-57
93. Wesseling J, van Driel D, Heymans HAS et al: Coumarins during pregnancy: long term effects on growth and development in school age children. Thromb Haemost, 2001; 85: 609-13
94. Bates SM, Greer IA, Hirsh J, Ginsberg JS: Use of antithrombotic agents during pregnancy: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest, 2004; 126: 627-44
95. Gonzalez CH, Vargas FR, Perez AB et al: Limb defi ciency with or without Moebius sequence in seven Brazilian children associated with misoprostol use in the fi rst trimester of pregnancy. Am J Med Genet, 1993; 47: 59-64
96. Fonseca W, Alencar AJC, Mota FSB, Coelho HLL: Misoprostol and congenital malformations. Lancet, 1991; 338: 56
97. da Silva Dal Pizzol T, Knop FP, Mengue SS: Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis. Reprod Toxicol, 2006; 22(4): 666-71
98. Scheinfeld N, Bangalore S: Facial edema induced by isotretinoin use: a case and a review of the side effects of isotretinoin. J Drugs Dermatol, 2006; 5(5): 467-68
99. Berard A, Azoulay L, Koren G et al: Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol, 2007; 63(2): 196-205
100. Chalmers RJ: Retinoid therapy - a real hazard for the developing embryo. Br J Obstet Gynaecol, 1992; 99(4): 276-78
101. Adams J: Similarities in genetic mental retardation and neuroteratogenic syndromes. Pharmacol Biochem Behav, 1996; 55(4): 683-90
102. Loureiro KD, Kao KK, Jones KL et al: Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A, 2005; 136(2): 117-21
103. Kubota Y, Shimotake T, Iwai N: Congenital anomalies in mice induced by etretinate. Eur J Pediatr Surg, 2000; 10(4): 248-51
104. Boucher N, Beaulac-Baillargeon L: Pregnancy prevention among women taking isotretinoin: failure to comply with the recommendations. Can Fam Physician, 2006; 52: 338-39
105. Cheetham TC, Wagner RA, Chiu G et al: A risk management program aimed at preventing fetal exposure to isotretinoin: retrospective cohort study. J Am Acad Dermatol, 2006; 55(3): 442-48. Epub 2006 Jul 13
106. Abroms L, Maibach E, Lyon-Daniel K, Feldman SR: What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med, 2006; 3(11): 483
107. Evans K, Hockey Weyer MU: Cleft anterior segment with maternal hypervitaminosis A. Br J Ophtalmol, 1991; 75: 691-92
108. Rothman KJ, Moore LL, Singer MR et al: Teratogenicity of high vitamin A intake. N Engl J Med, 1995; 333(21): 1369-73
109. Mastroiacovo P, Mazzone T, Addis A et al: High vitamin A intake in early pregnancy and major malformations: a multicenter prospective controlled study. Teratology, 1999; 59(1): 7-11
110. Martinez-Frias ML, Salvador J: Epidemiological aspects of prenatal exposure to high doses of vitamin A in Spain. Eur J Epidemiol, 1990; 6(2): 118-23
111. Ray JG, Vermeulen MJ, Koren G: Taking ACE inhibitors during early pregnancy: is it safe? Can Fam Physician, 2007; 53(9): 1439-40
112. Yip SK, Leung TN, Fung HY: Exposure to angiotensin-converting enzyme inhibitors during first trimester: is it safe to fetus? Acta Obstet Gynecol Scand, 1998; 77(5): 570-71
113. Centers for Disease Control and Prevention (CDC). Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy - United States, Canada, and Israel, 1987-1995. MMWR Morb Mortal Wkly Rep, 1997; 46(11): 240-42
114. Schaefer C: Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res A Clin Mol Teratol, 2003; 67(8): 591-94
115. Scialli AR, Lione A: ACE inhibitors and major congenital malformations. N Engl J Med, 2006; 355(12): 1280
116. Sealey JE, Itskovitz-Eldor J: ACE inhibitors and major congenital malformations. N Engl J Med, 2006; 355(12): 1280-81
117. Atallah AN: Angiotensin-converting enzyme inhibitors during the fi rst trimester of pregnancy increase the incidence of fetal malformation, whereas calcium intake (1.0 to 2.0 g/day) prevents preeclampsia. Sao Paulo Med J, 2006; 124(5): 243-44
118. Cunniff C, Jones KL, Phillipson J et al: Oligohydramnios sequence and renal tubular malformation associated with maternal enalapril use. Am J Obstet Gynecol, 1990; 162(1): 187-89
119. Burrows RF, Burrows EA: Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Aust NZ J Obstet Gynaecol, 1998; 38(3): 306-11
120. Shrim A, Berger H, Kingdom J et al: Prolonged exposure to angiotensin-converting enzyme inhibitors during pregnancy. Fetal toxicity could be reversible. Can Fam Physician, 2005; 51: 1335-37
121. Houlihan DD, Dennedy MC, Ravikumar N, Morrison JJ: Anti-hypertensive therapy and the feto-placental circulation: effects on umbilical artery resistance. J Perinat Med, 2004; 32(4): 315-19
122. Montan S: Drugs used in hypertensive diseases in pregnancy. Curr Opin Obst Gyn, 2004; 16(2): 111-15
123. Dumas G, Charachon R: Ototoxicity: etiology and issues. J Fam Pract, 1983; 16(3): 489-94
124. D'Alonzo BJ, Cantor AB: Ototoxicity of kanamycin in developing guinea pigs. An electrophysiological study. Acta Otolaryngol, 1982; 94(3-4): 203-12
125. Gilbert T, Lelievre-Pegorier M, Merlet-Benichou C. Immediate and longterm renal effects of fetal exposure to gentamicin. Pediatr Nephrol, 1990; 4(4): 445-50
126. Chahoud I, Stahlmann R, Merker HJ, Neubert D: Hypertension and nephrotoxic lesions in rats 1 year after prenatal exposure to gentamicin. Arch Toxicol, 1988; 62(4): 274-84
127. Hulton SA, Kaplan BS: Renal dysplasia associated with in utero exposure to gentamicin and corticosteroids. Am J Med Genet, 1995; 58(1): 91-93
128. Korzeniowski OM: Antibacterial agents in pregnancy. Infect Dis Clin North Am, 1995; 9(3): 639-51
129. Siddiqui MA, Janjua MZ: Effect of prenatal doxycycline administration on skeletal differentiation in long bones of Albino rat. Pak Med Assoc, 2002; 52(5): 211-14
130. Kutscher AH, Zegarelli EV, Tovell HM et al: Discoloration of deciduous teeth induced by administrations of tetracycline antepartum. Am J Obstet Gynecol, 1966; 96: 291-92
131. Cohlan Sq, Bevelander G, Tiamsic T: Growth inhibition of prematures receiving tetracycline. Am J Dis Child, 1963; 105: 453-61
132. Cohlan SQ: Tetracycline staining of teeth. Teratology, 1977; 15(1): 127-29
133. Schultz JC, Adamson JS, Workman WW, Norman TD: Fatal liver disease after intravenous administration of tetracycline in high dosage. N Engl J Med, 1963; 269: 999-1004
134. Norman TD, Schultz JC, Hoke RD: Fatal liver disease following the administration of tetracycline. South Med J, 1964; 57: 1038-42
135. Doll RC, Ringenberg OS, Yarbo JW: Antineoplastic agent and pregnancy. Sem Onc, 1989; 16: 337-46
136. Zemlickis D, Lishner M, Degendorfer P: Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med, 1992; 152: 573-76
137. Cardonick E, Iacobucci A: Use of chemotherapy during human pregnancy. Lancet Oncol, 2004; 5: 283-91
138. Del Campo M, Kosaki K, Bennett FC, Jones KL: Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology, 1999; 60(1): 10-12
139. Thiersch JB: Therapeutic abortions with folic acid antagonist 4-aminopteroylglutamic acid (4-amino PGA) administered by oral route. Am J Obstet Gynecol, 1952; 63: 1298-304
140. Warkany J: Aminopterin and methotrexate: Folic acid defi ciency. Teratology, 1978; 17: 353-57
141. Feldkamp M, Carey JC: Clinical teratology counseling and consultation case report: Low dose methorexate exposure in the early weeks of pregnancy. Teratology, 1993; 47: 533-39
142. Kirshon B, Wasserstrum N, Willis R et al: Teratogenic effects of fi rst trimester cyclophosphamide therapy. Obstet Gynecol, 1988; 72: 462
143. Paladini D, Vassallo M, D'Armiento MR et al: Prenatal detection of multiple fetal anomalies following inadvertent exposure to cyclophosphamide in the fi rst trimester of pregnancy. Birth Defects Res A Clin Mol Teratol, 2004; 70(2): 99-100
144. Meyer-Wittkopf M, Barth H, Emons G, Schmidt S: Fetal cardiac effects of doxorubicin therapy for carcinoma of the breast during pregnancy: case report and review of the literature. Ultrasound Obstet Gynecol, 2001; 18(1): 62-66
145. Liakopoulou A, Buttar HS, Nera EA: Effects of in utero exposure to cyclophosphamide in mice. Pregnancy outcome and observations of offspring during early postnatal life. Res Commun Chem Pathol Pharmacol, 1989; 64(2): 241-54
146. Briggs GG, Freeman RK, Yaffe SJ: Drugs in pregnancy and lactation, 6th edition, Baltimore: Lippincott Williams & Wilkins, 2002; 159-60
147. Raymond GV: Teratogen update: ergot and ergotamine. Teratology, 1995; 51(5): 344-47
148. Hughes HE, Goldstein DA: Birth defects following maternal exposure to ergotamine, beta blockers, and caffeine. J Med Genet, 1988; 25(6): 396-99
149. Smets K, Zecic A, Willems J: Ergotamine as a possible cause of Moebius sequence: additional clinical observation. J Child Neurol, 2004; 19(5): 398
150. Graf WD, Shepard TH: Uterine contraction in the development of Moebius syndrome. J Child Neurol, 1997; 12(3): 225-27
151. Acs N, Banhidy F, Puho E, Czeizel AE: A possible dose-dependent teratogenic effect of ergotamine. Reprod Toxicol, 2006; 22: 551-52
152. De Santis M, Straface G, Cavaliere AF et al: Teratological risk evaluation and prevention of voluntary abortion. Minerva Ginecol, 2006; 58(2): 91-99
153. Pole M, Einarson A, Pairaudeau N et al: Drug labeling and risk perceptions of teratogenicity: a survey of pregnancy Canadian women and their health professionals. J Clin Pharm, 2000; 40: 573-77
154. Hancock RL, Koren G, Einarson A, Ungar WJ: The effectiveness of Teratology Information service (TIS). Reprod Toxic, 2007; 23(2): 125-32
155. Atrash HK, Johnson K, Adams M et al: Preconception care for improving perinatal outcome: the time to act. Matern Child Health J, 2006; 10(Suppl.5): S3-11